



OCTOBER 2023

Does early treatment with highly effective DMT improve prognosis for people with MS?

Welcome to the DELIVER-MS newsletter. Some of the DELIVER investigators recently attended the European/ American MS conference in Milan. It was interesting to see the number of talks discussing the most appropriate ways to use existing DMTs. Induction, escalation, de-escalation were all discussed but we still lack consensus. We believe there is still a need for data to inform our approach to keeping patients safe and well in the long-term, particularly around safety.

12 more
participants
needed!

LONG-TERM EXTENSION


Several participants have now reached Month-48 and the majority are keen to continue into the DELIVER-MS long-term extension (LTE) study. Visits will remain very similar to those in month 12, 24, 36. **Ability will become the main focus** of the extension study (but we will continue to measure MRI changes, questionnaires and other important things like side-effects, tolerability of DMTs and employment status).

We thank sites and participants for their involvement in the DELIVER-MS LTE.

NEWS AND REMINDERS

- ◆ Please remember to record any DMT changes that occur, since this will be vital to our analysis.
- ◆ A reminder that 36M MRI **must be performed on the same MRI scanner as baseline MRI.**
- ◆ Once we are fully enrolled we will be planning a webinar for the public to report on the cohort and next steps.

OVERALL RECRUITMENT



FINAL THOUGHTS:

Can you contribute to us completing recruitment to the DELIVER-MS study? We are looking at less than one more participant per site now, and ***we are hugely grateful for all of your efforts.***